Ann Conkle
Apr 4, 2012

Targeted nanoparticles show success in first human clinical trials

Targeted therapeutic nanoparticles that accumulate in tumors while bypassing healthy cells have shown promising results in an ongoing clinical trial, according to a new paper. The nanoparticles feature a homing molecule that allows them to specifically attack cancer cells, and are the first such targeted particles to enter human clinical studies. Originally developed by researchers at MIT and Brigham and Women’s Hospital in Boston, the particles are designed to carry the chemotherapy drug docetaxel, used to treat lung, prostate and breast cancers, among others. In the study, which appears April 4 in the journal Science Translational Medicine, the researchers demonstrate the particles’ ability to target a receptor found on cancer cells and accumulate at tumor sites. The particles were also shown to be safe and effective: Many of the patients’ tumors shrank as a result of the treatment, even when they received lower doses than those usually administered. 

Companies
1
Patents
1
0 Comments
Related Articles
Ann Conkle
Mar 9, 2012
Nanotube technology leading to faster, lower-cost medical diagnostics
Researchers at Oregon State University have tapped into the extraordinary power of carbon nanotubes to increase the speed of biological... Read More
Ann Conkle
Mar 16, 2012
Nanopills release drugs directly from the inside of cells
Universitat Autonoma de Barcelona researchers have developed a new vehicle to release proteins with therapeutic effects. The vehicles are known... Read More
Ann Conkle
Mar 20, 2012
Nanotherapy: Delivering big radiation to brain tumors with tiny tools
For the past 40 years, radiation has been the most effective method for treating deadly brain tumors called glioblastomas. Unfortunately,... Read More